Mankind Pharma announced on Wednesday that it has partnered with BDR Pharmaceuticals to launch the oral anti-COVID-19 pill Molulife (Molnupiravir) in the country. The combination is a licensing agreement where production is handled by BDR Pharma and marketing, sales, promotion and distribution are handled by Mankind Pharma, the company said in a statement.
On Tuesday, the Drugs Controller General of India (DCGI) authorized the restricted use of the antiviral drug Molnupiravir in emergency situations for the treatment of COVID-19 in adult patients at high risk of disease progression. This launch further enhances the COVID-19 treatment portfolio in BDR’s product basket with the addition of generic Molnupiravir. We are delighted to be working with Mankind Pharma to take a step forward in the fight against the virus, ”said Raheel Shah, Director of Business Development at BDR Pharma.
Sanjay Koul, senior president of Mankind Pharma (sales and marketing), noted that a pill for COVID-19 would have to go miles to strengthen the defense against the battle of COVID-19. Humanity, with its motto “at the service of life”, will make Molulife available in every nook and cranny of the country, he added.
“The company is focused on providing a range of drugs for the management and treatment of COVID-19 in India,” Koul said.
(Edited by : Aditi Gautam)